Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Melanin Concentrating Hormone Signaling Deficits in Schizophrenia: Association With Memory and Social Impairments and Abnormal Sensorimotor Gating.

Tytuł :
Melanin Concentrating Hormone Signaling Deficits in Schizophrenia: Association With Memory and Social Impairments and Abnormal Sensorimotor Gating.
Autorzy :
Vawter MP; Department of Psychiatry and Human Behavior, School of Medicine, University of California, Irvine, CA.
Schulmann A; Department of Psychiatry and Human Behavior, School of Medicine, University of California, Irvine, CA.; Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA.
Alhassen L; Department of Psychiatry and Human Behavior, School of Medicine, University of California, Irvine, CA.
Alhassen W; Department of Pharmacology, School of Medicine, University of California, Irvine, CA.; Department of Pharmaceutical Sciences, University of California, Irvine, CA.
Hamzeh AR; John Curtin School of Medical Research, Australian National University, Canberra.
Sakr J; Department of Pharmaceutical Sciences, University of California, Irvine, CA.
Pauluk L; Department of Pharmacology, School of Medicine, University of California, Irvine, CA.
Yoshimura R; Department of Pharmacology, School of Medicine, University of California, Irvine, CA.
Wang X; Department of Pharmacology, School of Medicine, University of California, Irvine, CA.
Dai Q; Department of Pharmacology, School of Medicine, University of California, Irvine, CA.
Sanathara N; Department of Pharmacology, School of Medicine, University of California, Irvine, CA.
Civelli O; Department of Pharmacology, School of Medicine, University of California, Irvine, CA.; Department of Pharmaceutical Sciences, University of California, Irvine, CA.; Department of Developmental and Cell Biology, School of Medicine, University of California, Irvine, CA.
Alachkar A; Department of Pharmaceutical Sciences, University of California, Irvine, CA.
Pokaż więcej
Źródło :
The international journal of neuropsychopharmacology [Int J Neuropsychopharmacol] 2020 Mar 10; Vol. 23 (1), pp. 53-65.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język :
English
Imprint Name(s) :
Publication: 2015- : Oxford Oxford University Press
Original Publication: Cambridge, [England] : Cambridge University Press,
MeSH Terms :
Hypothalamic Hormones/*metabolism
Melanins/*metabolism
Memory Disorders/*physiopathology
Pituitary Hormones/*metabolism
Prefrontal Cortex/*metabolism
Receptors, Somatostatin/*deficiency
Receptors, Somatostatin/*metabolism
Schizophrenia/*metabolism
Schizophrenia/*physiopathology
Sensory Gating/*physiology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Animals ; Behavior, Animal/physiology ; Child ; Child, Preschool ; Disease Models, Animal ; Female ; Fetus ; Humans ; Infant ; Male ; Memory Disorders/etiology ; Mice ; Mice, Knockout ; Middle Aged ; Schizophrenia/complications ; Young Adult
References :
Eur Neuropsychopharmacol. 2014 May;24(5):822-35. (PMID: 24287012)
J Neurophysiol. 2010 Sep;104(3):1417-25. (PMID: 20592115)
J Neurosci. 2010 Jun 16;30(24):8263-73. (PMID: 20554878)
Biochem Biophys Res Commun. 1999 Aug 11;261(3):622-6. (PMID: 10441476)
Biol Psychiatry. 2007 Jan 15;61(2):174-80. (PMID: 16934771)
Peptides. 1999 Dec;20(12):1517-9. (PMID: 10698129)
Neuroscience. 2007 Jun 15;147(1):18-27. (PMID: 17512671)
Eur Neuropsychopharmacol. 2016 Nov;26(11):1826-1835. (PMID: 27617778)
Science. 2018 Dec 14;362(6420):. (PMID: 30545856)
J Neural Transm Gen Sect. 1992;89(1-2):1-10. (PMID: 1358122)
Biol Psychiatry. 2010 Jul 1;68(1):33-40. (PMID: 20434134)
Mol Cell Neurosci. 1993 Jun;4(3):271-84. (PMID: 19912933)
Nature. 2019 Sep;573(7772):61-68. (PMID: 31435019)
Lancet. 2004 Jun 19;363(9426):2063-72. (PMID: 15207959)
Mol Psychiatry. 2009 Apr;14(4):398-415, 347. (PMID: 19030002)
Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R749-58. (PMID: 15130877)
Behav Pharmacol. 2000 Jun;11(3-4):223-33. (PMID: 11103877)
PLoS One. 2014 Jun 12;9(6):e99961. (PMID: 24924345)
Psychol Bull. 1980 Nov;88(3):551-79. (PMID: 7003640)
Eur J Neurosci. 2005 May;21(10):2837-44. (PMID: 15926931)
Neuropsychopharmacology. 1994 May;10(3):199-205. (PMID: 7916917)
Endocrinology. 2005 Aug;146(8):3325-33. (PMID: 15905320)
Nature. 1999 Jul 15;400(6741):261-5. (PMID: 10421367)
Nat Neurosci. 2018 Aug;21(8):1117-1125. (PMID: 30050107)
Eur Neuropsychopharmacol. 2014 May;24(5):759-73. (PMID: 24342774)
PLoS One. 2013 May 07;8(5):e63136. (PMID: 23667582)
Trends Endocrinol Metab. 2000 Oct;11(8):299-303. (PMID: 10996523)
Arch Gen Psychiatry. 2006 Dec;63(12):1325-35. (PMID: 17146007)
PLoS One. 2011;6(7):e19286. (PMID: 21818251)
J Chem Neuroanat. 2010 Jan;39(1):51-62. (PMID: 19913090)
Mol Psychiatry. 2018 Feb;23(2):282-294. (PMID: 28809400)
Genome Biol. 2014 Feb 03;15(2):R29. (PMID: 24485249)
Nat Methods. 2005 Jun;2(6):419-26. (PMID: 15908920)
Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6772-7. (PMID: 19342492)
Nat Genet. 2018 Mar;50(3):381-389. (PMID: 29483656)
Sleep. 2013 Dec 01;36(12):1777. (PMID: 24293749)
Psychiatr Genet. 2012 Apr;22(2):62-9. (PMID: 22081064)
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3240-5. (PMID: 11867747)
Physiol Behav. 2008 Mar 18;93(4-5):842-50. (PMID: 18191424)
Biol Psychiatry. 2006 Mar 15;59(6):546-54. (PMID: 16256957)
Peptides. 2002 Jan;23(1):151-5. (PMID: 11814630)
Genes Brain Behav. 2004 Oct;3(5):287-302. (PMID: 15344922)
Neuropharmacology. 2018 Jan;128:22-32. (PMID: 28888943)
Endocrinology. 1997 Jan;138(1):351-5. (PMID: 8977423)
Sleep. 2013 Dec 01;36(12):1767-8. (PMID: 24293745)
Brain Res. 2019 Sep 15;1719:71-76. (PMID: 31121161)
Nature. 1996 Mar 21;380(6571):243-7. (PMID: 8637571)
Brain Res Bull. 2007 Sep 14;74(1-3):21-8. (PMID: 17683785)
Nat Methods. 2017 Apr;14(4):417-419. (PMID: 28263959)
Cell Metab. 2010 Nov 3;12(5):545-52. (PMID: 21035764)
Peptides. 1996;17(6):1063-73. (PMID: 8899828)
Am J Med Genet B Neuropsychiatr Genet. 2006 Jul 5;141B(5):524-33. (PMID: 16741940)
J Comp Neurol. 1992 May 8;319(2):218-45. (PMID: 1522246)
J Comp Neurol. 2001 Jun 18;435(1):26-40. (PMID: 11370009)
J Neuroendocrinol. 1992 Dec;4(6):709-17. (PMID: 21554658)
Neuropsychopharmacology. 2006 Jan;31(1):112-20. (PMID: 15988472)
Peptides. 2001 Jul;22(7):1043-7. (PMID: 11445232)
Nature. 1999 Jul 15;400(6741):265-9. (PMID: 10421368)
Peptides. 2002 Dec;23(12):2213-21. (PMID: 12535701)
FEBS Lett. 1999 Sep 3;457(3):522-4. (PMID: 10471841)
Hippocampus. 2008;18(2):125-34. (PMID: 17924525)
Grant Information :
R01 MH110928 United States MH NIMH NIH HHS; U01 MH103340 United States MH NIMH NIH HHS; R21 MH109956 United States MH NIMH NIH HHS; R01 MH105898 United States MH NIMH NIH HHS; R01 MH117291 United States MH NIMH NIH HHS; R01 MH117292 United States MH NIMH NIH HHS; R21 MH105881 United States MH NIMH NIH HHS; U01 MH116492 United States MH NIMH NIH HHS; HHSN271201300031C United States MH NIMH NIH HHS; R01 MH110927 United States MH NIMH NIH HHS; U01 MH103365 United States MH NIMH NIH HHS; R01 MH093725 United States MH NIMH NIH HHS; U01 MH116442 United States MH NIMH NIH HHS; R01 MH111721 United States MH NIMH NIH HHS; P50 MH096891 United States MH NIMH NIH HHS; R37 MH057881 United States MH NIMH NIH HHS; P50 MH066392 United States MH NIMH NIH HHS; P50 MH106934 United States MH NIMH NIH HHS; U01 MH116488 United States MH NIMH NIH HHS; U01 MH116489 United States MH NIMH NIH HHS; R01 MH110905 United States MH NIMH NIH HHS; R01 MH110920 United States MH NIMH NIH HHS; R01 MH117293 United States MH NIMH NIH HHS; R01 MH085542 United States MH NIMH NIH HHS; R01 MH110921 United States MH NIMH NIH HHS; U01 MH116438 United States MH NIMH NIH HHS; R01 MH075916 United States MH NIMH NIH HHS; R01 MH097276 United States MH NIMH NIH HHS; U01 MH103392 United States MH NIMH NIH HHS; U01 MH103339 United States MH NIMH NIH HHS; R01 MH109677 United States MH NIMH NIH HHS; R01 MH094714 United States MH NIMH NIH HHS; R21 MH102791 United States MH NIMH NIH HHS; R21 MH105853 United States MH NIMH NIH HHS; U01 MH116441 United States MH NIMH NIH HHS; R01 MH109715 United States MH NIMH NIH HHS; U01 MH116487 United States MH NIMH NIH HHS; R01 MH110926 United States MH NIMH NIH HHS; P50 MH084053 United States MH NIMH NIH HHS; U01 MH103346 United States MH NIMH NIH HHS; R21 MH103877 United States MH NIMH NIH HHS; R01 MH109897 United States MH NIMH NIH HHS
Substance Nomenclature :
0 (Hypothalamic Hormones)
0 (MCHR1 protein, human)
0 (Mchr1 protein, mouse)
0 (Melanins)
0 (Pituitary Hormones)
0 (Receptors, Somatostatin)
67382-96-1 (melanin-concentrating hormone)
Entry Date(s) :
Date Created: 20190930 Date Completed: 20201130 Latest Revision: 20210414
Update Code :
20210623
PubMed Central ID :
PMC7442395
DOI :
10.1093/ijnp/pyz051
PMID :
31563948
Czasopismo naukowe
Background: Evidence from anatomical, pharmacological, and genetic studies supports a role for the neuropeptide melanin concentrating hormone system in modulating emotional and cognitive functions. Genome-wide association studies revealed a potential association between the melanin concentrating hormone receptor (MCHR1) gene locus and schizophrenia, and the largest genome-wide association study conducted to date shows a credible genome-wide association.
Methods: We analyzed MCHR1 and pro-melanin concentrating hormone RNA-Seq expression in the prefrontal cortex in schizophrenia patients and healthy controls. Disruptions in the melanin concentrating hormone system were modeled in the mouse brain by germline deletion of MCHR1 and by conditional ablation of melanin concentrating hormone expressing neurons using a Cre-inducible diphtheria toxin system.
Results: MCHR1 expression is decreased in the prefrontal cortex of schizophrenia samples (false discovery rate (FDR) P < .05, CommonMind and PsychEncode combined datasets, n = 901) while pro-melanin concentrating hormone is below the detection threshold. MCHR1 expression decreased with aging (P = 6.6E-57) in human dorsolateral prefrontal cortex. The deletion of MCHR1 was found to lead to behavioral abnormalities mimicking schizophrenia-like phenotypes: hyperactivity, increased stereotypic and repetitive behavior, social impairment, impaired sensorimotor gating, and disrupted cognitive functions. Conditional ablation of pro-melanin concentrating hormone neurons increased repetitive behavior and produced a deficit in sensorimotor gating.
Conclusions: Our study indicates that early disruption of the melanin concentrating hormone system interferes with neurodevelopmental processes, which may contribute to the pathogenesis of schizophrenia. Further neurobiological research on the developmental timing and circuits that are affected by melanin concentrating hormone may lead to a therapeutic target for early prevention of schizophrenia.
(© The Author(s) 2019. Published by Oxford University Press on behalf of CINP.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies